Mi-BMSCs alleviate inflammation and fibrosis in CCl₄-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling.

"Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Funding This work was Supported by Major scientific and technological innovation project of 10.13039/501100007194Wenzhou Science and Technology Bureau (Grant No. ZY2021009), Natural Science Foundation of Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province (No. G2023003), 10.13039/501100016983Shanghai Clinical Research Center for Interventional Medicine (NO.19MC1910300), the 10.13039/501100001809National Natural Science Foundation of China (Grant No.81972233), 10.13039/100007835Discipline Cluster of Oncology, Wenzhou Medical University, China (NO. z2-2023015), 10.13039/501100004731Zhejiang Provincial Natural Science Foundation of China (LY24H160028), Wenzhou high-level innovation team (Development and application team of functional liver cancer-on-a-chip)."